Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Preliminary Results of a Phase 1/2 Clinical Trial of Cndo-109-Activated Allogeneic Natural Killer Cells in High Risk Acute Myelogenous Leukemia Patients in First Complete Remission

Todd A. Fehniger, MD PhD, Robert K Stuart, MD, Sarah A. Cooley, MD MS, Jeffrey S. Miller, MD, Julie Curtsinger, PhD, Timothy Mark Hillman, MSc, Nova Silver, RN, Michael Szarek, PhD, Mark W Lowdell, BSc, MSc, PhD FRCPath, Leonid Gorelik, PhD, Eric Rowinsky, MD

Blood (2014) 124 (21): 2320.

https://doi.org/10.1182/blood.V124.21.2320.2320

Published: 2014

Journal Articles

SL-501, a Next-Generation Targeted Therapy Directed to the IL-3 Receptor (IL-3R), Possesses Preclinical Anti-Tumor Activity Against Hodgkin’s and Non-Hodgkin’s Lymphoma

Janice Chen, PhD, Vince Macri, MA, Pedro Herrera, MA, Christopher Brooks, PhD, Eric Rowinsky, MD

Blood (2014) 124 (21): 4500.

https://doi.org/10.1182/blood.V124.21.4500.4500

Published: 2014

Journal Articles

SL-401, a Novel Targeted Therapy Directed to the Interleukin-3 Receptor (IL-3R), Blocks Plasmacytoid Dendritic Cell (pDC)-Triggered Myeloma Cell Growth and Prevents Osteoclastogenesis

Arghya Ray, PhD, Deepika Sharma Das, PhD, Durgadevi Ravillah, PhD, Yan Song, PhD, Vincent Macri, Christopher Brooks, PhD, Eric Rowinsky, MD, Paul G. Richardson, Dharminder Chauhan, PhD, Kenneth C. Anderson, MD

Blood (2014) 124 (21): 3441.

https://doi.org/10.1182/blood.V124.21.3441.3441

Published: 2014

Journal Articles

Anti-Leukemia Efficacy and Mechanisms of Action of SL-101, a Novel Anti-CD123 Antibody-Conjugate in Acute Myeloid Leukemia

Lina Han, PhD, Eric Rowinsky, MD, Christopher Brooks, PhD, Tomasz Zal, M. Anna Zal, Jared K Burks, PhD, Jin Zhou, MD PhD, Stefan O. Ciurea, MD, Gheath Alatrash, Jorge E. Cortes, Hagop M. Kantarjian, MD, Michael Andreeff, MD PhD, Farhad Ravandi, MD, Marina Konopleva, MD PhD

Blood (2014) 124 (21): 981.

https://doi.org/10.1182/blood.V124.21.981.981

Published: 2014

Journal Articles

SL-401, a Targeted Therapy Directed to the Interleukin-3 Receptor (IL-3R), Shows Cytotoxic Activity Against Hairy Cell Leukemia

Christopher Brooks, PhD, Janice Chen, PhD, David M. Lucas, PhD, Natarajan Muthusamy, DVM, PhD, Ivan Bergstein, MD, Eric Rowinsky, MD

Blood (2014) 124 (21): 5663.

https://doi.org/10.1182/blood.V124.21.5663.5663

Published: 2014

Journal Articles

Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients

Arthur E. Frankel, Jung H. Woo, Chul Ahn, Naveen Pemmaraju, Bruno C. Medeiros, Hetty E. Carraway, Olga Frankfurt, Stephen J. Forman, Xuezhong A. Yang, Marina Konopleva, Francine Garnache-Ottou, Fanny Angelot-Delettre, Christopher Brooks, Michael Szarek, Eric Rowinsky

Blood (2014) 124 (3): 385–392.

https://doi.org/10.1182/blood-2014-04-566737

Published: 2014

Journal Articles

SL-401, a Targeted Therapy Directed To The Interleukin-3 Receptor (IL-3R), Possesses Preclinical Cytotoxic Activity Against Chronic Eosinophilic Leukemia

Christopher Brooks, PhD, Vincent Macri, Arnaldo Albini, MD, Ivan Bergstein, MD, Eric Rowinsky, MD

Blood (2013) 122 (21): 4104.

https://doi.org/10.1182/blood.V122.21.4104.4104

Published: 2013

Journal Articles

Preclinical Studies Of SL-401, a Targeted Therapy Directed To The Interleukin-3 Receptor (IL3-R), In Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Potent Activity In BPDCN Cell Lines, Primary Tumor, and In An In Vivo Model

Delettre Fanny, PhD, Arthur E. Frankel, MD, Estelle Seilles, PhD, Sabeha Biichle, Bsc, Eric Deconninck, MD, Francis Bonnefoy, PhD, Baptiste Lamarthee, PhD Student, Christopher L. Brooks, PhD, Eric Rowinsky, MD, Philippe Saas, Ph.D., Francine Garnache Ottou, PhD

Blood (2013) 122 (21): 3942.

https://doi.org/10.1182/blood.V122.21.3942.3942

Published: 2013

Journal Articles

SL-401, A Novel Targeted Therapy Directed To The Interleukin-3 Receptor (IL-3R), Inhibits Plasmacytoid Dendritic Cell (pDC)-Induced Myeloma Cell Growth and Overcomes Drug Resistance

Arghya Ray, Ph.D, Deepika Sharma Das, Ph.D., Ze Tian, Ph.D, Vincent Macri, Christopher L. Brooks, PhD, Paul G. Richardson, MD, Eric Rowinsky, MD, Dharminder Chauhan, PhD, Kenneth C. Anderson, MD

Blood (2013) 122 (21): 3170.

https://doi.org/10.1182/blood.V122.21.3170.3170

Published: 2013

Journal Articles

An Update On The Robust Clinical Activity Of SL-401, a Targeted Therapy Directed To The Interleukin-3 Receptor On Cancer Stem Cells and Tumor Bulk, In Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Arthur E. Frankel, MD, Jung H. Woo, PhD, Jeremy P. Mauldin, PhD, Hetty E. Carraway, MD, MBA, Olga Frankfurt, MD, Stephen J. Forman, MD, Sumithira Vasu, MBBS, Naveen Pemmaraju, MD, Marina Konopleva, MD, PhD, Donna E. Hogge, MD, PhD, FRCPC, Francine Garanache-Ottou, Ph.D., Fanny Angelot-Delettre, PhD, Christopher Brooks, PhD, Michael Szarek, PhD, Ivan Bergstein, MD, Eric Rowinsky, MD

Blood (2013) 122 (21): 2682.

https://doi.org/10.1182/blood.V122.21.2682.2682

Published: 2013

Journal Articles

Leukemia Stem Cell Marker CD123 (IL-3R alpha) Predicts Minimal Residual Disease and Relapse, Providing a Valid Target For SL-101 In Acute Myeloid Leukemia With FLT3-ITD Mutations

Lina Han, PhD, Jeffrey L. Jorgensen, MD, PhD, Sa A. Wang, MD, Xuelin Huang, Graciela M Nogueras González, Christopher Brooks, PhD, Eric Rowinsky, MD, Mark Levis, MD, PhD, Jin Zhou, Stefan O. Ciurea, MD, Gheath Alatrash, DO, PhD, Jorge E. Cortes, MD, Hagop M. Kantarjian, MD, Michael Andreeff, MD, PhD, Farhad Ravandi, MD, Marina Konopleva, MD, PhD

Blood (2013) 122 (21): 359.

https://doi.org/10.1182/blood.V122.21.359.359

Published: 2013

Journal Articles

SL-401, A Targeted Therapy Directed to the Interleukin-3 Receptor Present On Leukemia Blasts and Cancer Stem Cells, Is Active As a Single Agent in Patients with Advanced AML

Marina Konopleva, MD, PhD, Donna E. Hogge, MD, PhD, FRCPC, David A. Rizzieri, MD, Thomas P. Cirrito, PhD, Steven M. Kornblau, MD, PhD, Gautam Borthakur, M.D., Carol Bivins, RN, Guillermo Garcia-Manero, MD, Tapan M. Kadia, M.D., Farhad Ravandi, MD, Michael Andreeff, MD, PhD, Jorge E. Cortes, MD, Kenneth Hoberman, Michael Szarek, PhD, Eric Rowinsky, MD, Ivan Bergstein, MD, Hagop M. Kantarjian, MD, Arthur E. Frankel, MD

Blood (2012) 120 (21): 3625.

https://doi.org/10.1182/blood.V120.21.3625.3625

Published: 2012

Journal Articles

SL-101, a Novel Monoclonal Antibody-Conjugate That Targets Interleukin-3 Receptor Alpha (CD123), Possesses Preclinical Anti-Tumor Activity Against Hodgkin's Lymphoma.

Christopher L. Brooks, PhD, Thomas P. Cirrito, PhD, Kenneth Hoberman, Eric Rowinsky, MD

Blood (2012) 120 (21): 2768.

https://doi.org/10.1182/blood.V120.21.2768.2768

Published: 2012

NARROW

Preliminary Results of a Phase 1/2 Clinical Trial of Cndo-109-Activated Allogeneic Natural Killer Cells in High Risk Acute Myelogenous Leukemia Patients in First Complete Remission

SL-501, a Next-Generation Targeted Therapy Directed to the IL-3 Receptor (IL-3R), Possesses Preclinical Anti-Tumor Activity Against Hodgkin’s and Non-Hodgkin’s Lymphoma

SL-401, a Novel Targeted Therapy Directed to the Interleukin-3 Receptor (IL-3R), Blocks Plasmacytoid Dendritic Cell (pDC)-Triggered Myeloma Cell Growth and Prevents Osteoclastogenesis

Anti-Leukemia Efficacy and Mechanisms of Action of SL-101, a Novel Anti-CD123 Antibody-Conjugate in Acute Myeloid Leukemia

SL-401, a Targeted Therapy Directed to the Interleukin-3 Receptor (IL-3R), Shows Cytotoxic Activity Against Hairy Cell Leukemia

Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients

SL-401, a Targeted Therapy Directed To The Interleukin-3 Receptor (IL-3R), Possesses Preclinical Cytotoxic Activity Against Chronic Eosinophilic Leukemia

Preclinical Studies Of SL-401, a Targeted Therapy Directed To The Interleukin-3 Receptor (IL3-R), In Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Potent Activity In BPDCN Cell Lines, Primary Tumor, and In An In Vivo Model

SL-401, A Novel Targeted Therapy Directed To The Interleukin-3 Receptor (IL-3R), Inhibits Plasmacytoid Dendritic Cell (pDC)-Induced Myeloma Cell Growth and Overcomes Drug Resistance

An Update On The Robust Clinical Activity Of SL-401, a Targeted Therapy Directed To The Interleukin-3 Receptor On Cancer Stem Cells and Tumor Bulk, In Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Leukemia Stem Cell Marker CD123 (IL-3R alpha) Predicts Minimal Residual Disease and Relapse, Providing a Valid Target For SL-101 In Acute Myeloid Leukemia With FLT3-ITD Mutations

SL-401, A Targeted Therapy Directed to the Interleukin-3 Receptor Present On Leukemia Blasts and Cancer Stem Cells, Is Active As a Single Agent in Patients with Advanced AML

SL-101, a Novel Monoclonal Antibody-Conjugate That Targets Interleukin-3 Receptor Alpha (CD123), Possesses Preclinical Anti-Tumor Activity Against Hodgkin's Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only